Details of the Drug

General Information of Drug (ID: DM89JLN)

Drug Name
Apixaban
Synonyms
GG2; BMS 562247-01; BMS-562247; Eliquis (TN); BMS-562247-01; Apixaban (JAN/USAN/INN); BMS-562247-01, Apixaban; Ro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahyd
Indication
Disease Entry ICD 11 Status REF
Thrombosis DB61-GB90 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 459.5
Topological Polar Surface Area (xlogp) 2.2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Bioavailability
The bioavailability of drug is 50% [3]
Clearance
The clearance of drug is 3.3 L/h [3]
Elimination
56% of an orally administered dose is recovered in the feces and 24.5-28.8% of the dose is recovered in the urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 12.7 +/- 8.55 hours [3]
Metabolism
The drug is metabolized via the CYP3A4 [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.13% [4]
Vd
The volume of distribution (Vd) of drug is approximately 21 L [5]
Chemical Identifiers
Formula
C25H25N5O4
IUPAC Name
1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide
Canonical SMILES
COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
InChI
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
InChIKey
QNZCBYKSOIHPEH-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10182969
ChEBI ID
CHEBI:72296
CAS Number
503612-47-3
DrugBank ID
DB06605
TTD ID
D0I5HF
VARIDT ID
DR00211
INTEDE ID
DR0122
ACDINA ID
D00040

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Inhibitor [6], [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [11]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Thrombosis
ICD Disease Classification DB61-GB90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Coagulation factor Xa (F10) DTT F10 4.84E-02 -0.28 -0.9
P-glycoprotein 1 (ABCB1) DTP P-GP 2.04E-02 -1.13E+00 -1.00E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 2.10E-01 3.71E-01 7.59E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.73E-04 1.53E-01 7.44E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 1.44E-01 -3.59E-01 -1.14E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.51E-02 1.53E+00 1.16E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.02E-01 -2.84E-01 -7.34E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.62E-02 -4.23E-01 -1.25E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.84E-01 -1.61E-01 -3.61E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Apixaban
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Apixaban and Brilinta. Thrombosis [DB61-GB90] [86]
Coadministration of a Drug Treating the Disease Different from Apixaban (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Apixaban due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [86]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Apixaban caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [87]
Arn-509 DMT81LZ Major Increased metabolism of Apixaban caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [86]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Apixaban due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [86]
Emapalumab DMZG5WL Moderate Altered metabolism of Apixaban due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [86]
Siltuximab DMGEATB Moderate Altered metabolism of Apixaban due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [86]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Apixaban caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [86]
Erdafitinib DMI782S Moderate Decreased clearance of Apixaban due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [88]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Apixaban caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [87]
HKI-272 DM6QOVN Moderate Decreased clearance of Apixaban due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [86]
Tucatinib DMBESUA Major Decreased metabolism of Apixaban caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [89]
PF-04449913 DMSB068 Moderate Decreased clearance of Apixaban due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [86]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Apixaban and Levomilnacipran. Chronic pain [MG30] [90]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Apixaban and Regorafenib. Colorectal cancer [2B91] [86]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Apixaban and Intedanib. Colorectal cancer [2B91] [91]
Ulipristal DMBNI20 Moderate Decreased clearance of Apixaban due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [86]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Apixaban and Ardeparin. Coronary thrombosis [BA43] [92]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Apixaban caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [86]
Lumacaftor DMCLWDJ Major Increased metabolism of Apixaban caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [86]
Ivacaftor DMZC1HS Moderate Decreased clearance of Apixaban due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [86]
MK-8228 DMOB58Q Moderate Decreased clearance of Apixaban due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [86]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Apixaban and Danaparoid. Deep vein thrombosis [BD71] [92]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Apixaban and Vilazodone. Depression [6A70-6A7Z] [90]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Apixaban and Vortioxetine. Depression [6A70-6A7Z] [90]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Apixaban and Desvenlafaxine. Depression [6A70-6A7Z] [90]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Apixaban and Apigenin. Discovery agent [N.A.] [93]
Stiripentol DMMSDOY Moderate Decreased metabolism of Apixaban caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [86]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Apixaban caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [87]
Tazemetostat DMWP1BH Major Increased risk of bleeding by the combination of Apixaban and Tazemetostat. Follicular lymphoma [2A80] [86]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Apixaban and Avapritinib. Gastrointestinal stromal tumour [2B5B] [86]
Boceprevir DMBSHMF Major Decreased metabolism of Apixaban caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [89]
Daclatasvir DMSFK9V Moderate Decreased clearance of Apixaban due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [86]
GS-5885 DMSL3DX Moderate Decreased clearance of Apixaban due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [86]
GS-9857 DMYU6P5 Moderate Decreased clearance of Apixaban due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [86]
Cobicistat DM6L4H2 Major Decreased clearance of Apixaban due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [89]
BMS-201038 DMQTAGO Moderate Decreased clearance of Apixaban due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [86]
Levamlodipine DM92S6N Moderate Decreased metabolism of Apixaban caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [86]
Lesinurad DMUR64T Moderate Increased metabolism of Apixaban caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [87]
Suvorexant DM0E6S3 Moderate Decreased clearance of Apixaban due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [86]
Crizotinib DM4F29C Moderate Decreased clearance of Apixaban due to the transporter inhibition by Crizotinib. Lung cancer [2C25] [86]
Ceritinib DMB920Z Moderate Decreased metabolism of Apixaban caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [86]
PF-06463922 DMKM7EW Moderate Increased metabolism of Apixaban caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [87]
Capmatinib DMYCXKL Moderate Decreased clearance of Apixaban due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [86]
Selpercatinib DMZR15V Moderate Decreased metabolism of Apixaban caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [86]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Apixaban and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [94]
Idelalisib DM602WT Moderate Decreased metabolism of Apixaban caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [86]
IPI-145 DMWA24P Moderate Decreased metabolism of Apixaban caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [86]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Apixaban and Acalabrutinib. Mature B-cell lymphoma [2A85] [95]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Apixaban and Ibrutinib. Mature B-cell lymphoma [2A85] [96]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Apixaban and Ponatinib. Mature B-cell lymphoma [2A85] [97]
Vemurafenib DM62UG5 Moderate Decreased clearance of Apixaban due to the transporter inhibition by Vemurafenib. Melanoma [2C30] [86]
LGX818 DMNQXV8 Moderate Increased metabolism of Apixaban caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [98]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Apixaban caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [86]
Lasmiditan DMXLVDT Moderate Decreased clearance of Apixaban due to the transporter inhibition by Lasmiditan. Migraine [8A80] [99]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Apixaban caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [86]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Apixaban and Ruxolitinib. Myeloproliferative neoplasm [2A20] [86]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Apixaban and Vorapaxar. Myocardial infarction [BA41-BA43] [100]
Rolapitant DM8XP26 Moderate Decreased clearance of Apixaban due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [101]
Netupitant DMEKAYI Moderate Decreased metabolism of Apixaban caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [86]
Entrectinib DMMPTLH Moderate Decreased clearance of Apixaban due to the transporter inhibition by Entrectinib. Non-small cell lung cancer [2C25] [86]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Apixaban and Nepafenac. Osteoarthritis [FA00-FA05] [102]
Rucaparib DM9PVX8 Moderate Decreased clearance of Apixaban due to the transporter inhibition by Rucaparib. Ovarian cancer [2C73] [86]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Apixaban and MK-4827. Ovarian cancer [2C73] [86]
Istradefylline DM20VSK Moderate Decreased clearance of Apixaban due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [86]
Abametapir DM2RX0I Moderate Decreased metabolism of Apixaban caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [103]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Apixaban and Choline salicylate. Postoperative inflammation [1A00-CA43] [104]
Ixekizumab DMXW92T Moderate Altered metabolism of Apixaban due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [86]
Golimumab DMHZV7X Moderate Altered metabolism of Apixaban due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [86]
Sarilumab DMOGNXY Moderate Altered metabolism of Apixaban due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [86]
Voxelotor DMCS6M5 Moderate Decreased clearance of Apixaban due to the transporter inhibition by Voxelotor. Sickle-cell disorder [3A51] [86]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Apixaban caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [86]
Larotrectinib DM26CQR Moderate Decreased metabolism of Apixaban caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [86]
LEE011 DMMX75K Moderate Decreased metabolism of Apixaban caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [86]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Apixaban and Curcumin. Solid tumour/cancer [2A00-2F9Z] [105]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Apixaban and Plicamycin. Testicular cancer [2C80] [86]
Fostamatinib DM6AUHV Moderate Decreased clearance of Apixaban due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [106]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Apixaban and Betrixaban. Venous thromboembolism [BD72] [86]
⏷ Show the Full List of 77 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Apixaban 2.5 mg tablet 2.5 mg Oral Tablet Oral
Apixaban 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6390).
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009 Jan;37(1):74-81. doi: 10.1124/dmd.108.023143. Epub 2008 Oct 2.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Pfizer. Product Development Pipeline. March 31 2009.
7 Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost. 2014 Sep;12(9):1545-53.
8 Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35.
9 Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27.
10 In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58.
11 Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
12 Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
23 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
24 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
25 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
26 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
27 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
28 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
29 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
30 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
31 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
32 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
33 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
34 Drug Interactions Flockhart Table
35 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
36 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
37 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
38 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
39 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
40 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
41 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
42 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
43 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
44 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
45 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
46 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
47 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
48 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
49 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
50 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
51 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
52 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
53 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
54 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
55 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
56 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
57 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
58 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
59 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
60 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
61 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
62 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
63 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
64 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
65 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
66 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
67 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
68 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
69 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
70 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
71 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
72 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
73 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
74 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
75 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
76 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
77 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
78 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
79 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
80 Company report (Portola)
81 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
82 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
83 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
84 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
85 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
86 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
87 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
88 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
89 Cerner Multum, Inc. "Australian Product Information.".
90 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
91 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
92 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
93 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
94 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
95 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
96 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
97 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
98 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
99 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
100 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
101 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
102 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
103 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
104 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
105 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
106 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.